GSK plc (NYSE:GSK) Shares Sold by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC reduced its holdings in GSK plc (NYSE:GSK - Free Report) by 68.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,930 shares of the pharmaceutical company's stock after selling 23,951 shares during the quarter. Mount Yale Investment Advisors LLC's holdings in GSK were worth $370,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. FMR LLC lifted its position in shares of GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC increased its stake in GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock valued at $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Primecap Management Co. CA raised its holdings in GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company's stock worth $607,222,000 after purchasing an additional 342,365 shares during the last quarter. Provident Trust Co. boosted its position in GSK by 1.7% during the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company's stock worth $161,623,000 after purchasing an additional 66,765 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC boosted its position in GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock worth $144,803,000 after purchasing an additional 833,080 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Trading Down 0.4 %

Shares of NYSE:GSK traded down $0.16 during trading on Friday, reaching $35.20. The stock had a trading volume of 5,112,110 shares, compared to its average volume of 3,683,507. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The stock has a market cap of $72.96 billion, a P/E ratio of 22.86, a PEG ratio of 1.37 and a beta of 0.63. The business has a fifty day moving average price of $34.07 and a 200-day moving average price of $37.68. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92.

Analyst Upgrades and Downgrades

GSK has been the subject of several research reports. StockNews.com downgraded GSK from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, January 21st. Guggenheim cut shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a "buy" rating to a "hold" rating and cut their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six research analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.